Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- Citi initiates UiPath coverage with Buy rating and $23 target
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Alibaba (BABA) PT Lowered to $165 at Bernstein SocGen Group
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Sarepta Therapeutics (SRPT) PT Lowered to $192 at RBC Capital; Now a Full-Fledged Gene Therapy Company
February 28, 2019 6:51 AM ESTRBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $192.00 (from $199.00) while maintaining a Outperform rating.
"We believe this quarter is marking the emergence of SRPT as a full-fledged gene therapy company and leader in neuro GT drug... More
Sarepta Therapeutics (SRPT) PT Raised to $213 at Cowen
February 28, 2019 6:21 AM ESTCowen analyst Ritu Baral raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $213.00 (from $178.00) while maintaining a Outperform rating.
Baral commented, "SRPT reported 4Q18 with pre-announced Exondys revenues only slightly below consensus but meeting FY18 guidance. SRPT provided timeline updates for its... More
Sarepta Therapeutics (SRPT) Tops Q4 EPS by 19c, Revenues Miss
February 27, 2019 4:15 PM ESTSarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($0.85), $0.19 better than the analyst estimate of ($1.04). Revenue for the quarter came in at $84.42 million versus the consensus estimate of $86.02 million.
2018 was a year of transformation for Sarepta. We continued to execute commercially, announced unprecedented early results... More
